On February 2, Indonesian Ministry of Health’s immunization program spokesperson, Siti Nadia Tarmizi, said that on the same day, the country had received raw materials from China’s Sinovac to produce 10 million. dose of COVID-19 vaccine.
This is the fourth batch of vaccines the country has received from, Ms. Siti said Sinovac and will be used by public service workers during phase 2 of the program national vaccination. This phase will target 17.4 million public employees working in areas at risk of virus infection SARS-CoV-2.
Nadia also said the vaccination program for the 1.5 million health workers will be completed by the end of February.
According to the data of Ministry of Health Indonesiaas of 1 February, 539,532 health workers had the first shot of COVID-19 vaccine and another 35,406 people had a second shot.
Meanwhile, Indonesia’s Health Ministry Secretary-General Oscar Primadi said that to date, Indonesia has received 28 million doses of COVID-19 vaccine from Sinovac, of which 3 million are ready for use and 25 million in the form of raw materials.
Indonesian officials said of the raw materials received on January 12, the country is processing 15 million doses of raw materials and is expected to be ready for use on February 11. Meanwhile, raw materials received on 2/2 will start to be processed from February 13 and expected to be completed on March 20.
To date, Indonesia has received commitments to supply and order a total of 663 million doses of vaccine from British AstraZeneca, Sinovac of China, Novavax of the US and Canada and Pfizer of the US. The country also officially kicked off its national vaccination program against COVID-19 on January 13, with the goal of vaccinating 181.5 million people within 15 months.
[Dịch COVID-19: Đông Nam Á tiếp tục ghi nhận các ca nhiễm mới]
Meanwhile, in Thailand, a health official in this country said that Johnson & Johnson (J&J) is currently completing the application for a license to use COVID-19 vaccine of the company in this country.
Surachoke Tangwiwat, Deputy Secretary General of the Food and Drug Administration (FDA) Indonesia, said the agency had received some documents for J&J’s vaccine evaluation from the end of last month. It is expected that the review process will take place within 30 days after J&J has provided enough documents.
Thus, the Johnson & Johnson vaccine is the third vaccine licensed in Thailand, after the AstraZeneca vaccine (UK) and the Sinovac (China) vaccine. Last month, Thai officials issued a one-year emergency permit for AstraZeneca’s vaccine.
Thai health officials said that the first 50,000 doses of the vaccine from AstraZeneca and 200,000 doses from Sinovac will be delivered in February. The government said that all preparations are underway to prepare for vaccination. in large scale since June, mainly using 61 million doses of AstraZeneca’s domestically produced AstraZeneca vaccine and 2 million previously licensed Sinovac doses./.